Martingale Asset Management L P Purchases 3,083 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Martingale Asset Management L P boosted its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 6.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 48,460 shares of the company’s stock after purchasing an additional 3,083 shares during the quarter. Martingale Asset Management L P’s holdings in Kiniksa Pharmaceuticals were worth $1,211,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. CWM LLC raised its holdings in Kiniksa Pharmaceuticals by 443.0% in the third quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares in the last quarter. Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals during the first quarter valued at $71,000. nVerses Capital LLC bought a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at $80,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Kiniksa Pharmaceuticals during the second quarter valued at $100,000. Finally, Lynx1 Capital Management LP bought a new position in shares of Kiniksa Pharmaceuticals during the second quarter valued at $177,000. Institutional investors own 53.95% of the company’s stock.

Analyst Ratings Changes

KNSA has been the subject of several analyst reports. Evercore ISI raised their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average price target of $36.60.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $22.08 on Monday. Kiniksa Pharmaceuticals, Ltd. has a one year low of $15.82 and a one year high of $28.15. The stock has a market capitalization of $1.59 billion, a PE ratio of -157.71 and a beta of 0.35. The business’s fifty day moving average is $23.95 and its 200 day moving average is $22.96.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million for the quarter, compared to analysts’ expectations of $111.51 million. During the same period last year, the business earned ($0.20) earnings per share. The company’s quarterly revenue was up 67.4% on a year-over-year basis. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $24.99, for a total value of $437,325.00. Following the transaction, the chief operating officer now directly owns 116,975 shares of the company’s stock, valued at approximately $2,923,205.25. This trade represents a 13.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the transaction, the insider now directly owns 52,038 shares in the company, valued at $1,359,232.56. The trade was a 53.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 95,192 shares of company stock valued at $2,479,390. Insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.